Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 19–20
HOS-086301 · Präparat HOS-083284
19
Ritonavir effects on Non-antiretroviral Co-administered Medicinal Products
Co-administered Medicinal Products Dose of Co- Dose of Effect on Co- Effect on Co-
administered NORVIR (mg) administered administered
Medicinal Products Medicinal Medicinal Products
(mg) Products Cmax
AUC
Simeprevir 200 qd 100 q12h ↑ 7.2-fold ↑ 4.7-fold
Ritonavir increases plasma concentrations of simeprevir as a result of CYP3A4
inhibition. It is not recommended to co-administer ritonavir with simeprevir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage a0f22869affe43175f29e712ef579b814dac1798d40b31c01cde5d37f0801aa6 · Zeichen 42137–43144 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 52
HOS-086471 · Präparat HOS-083284
HCV Protease Inhibitor
Simeprevir 200 qd 100 q12h ↑ 7.2-fold ↑ 4.7-fold
Ritonavir increases plasma concentrations of simeprevir as a result of CYP3A4 inhibition.
It is not recommended to co-administer ritonavir with simeprevir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage ef35a6871e735da400c7b57e7650b79be631515434468d835c9617d1abb87a39 · Zeichen 43971–44356 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 23–24
HOS-108925 · Präparat HOS-093083
23
Glecaprevir/pibrentasvir Serum concentrations may be Concomitant administration of
increased due to P-glycoprotein, glecaprevir/pibrentasvir and
BCRP and OATP1B inhibition by Kaletra is not recommended due
lopinavir/ritonavir. to an increased risk of ALT
elevations associated with
increased glecaprevir exposure.
Sofosbuvir/velpatasvir/ Serum concentrations of It is not recommended to
voxilaprevir sofosbuvir, velpatasvir and coadminister Kaletra and
voxilaprevir may be increased due sofosbuvir/velpatasvir/
to P-glycoprotein, BCRP and voxilaprevir.
OATP1B1/3 inhibition by
lopinavir/ritonavir. However,
only the increase in voxilaprevir
exposure is considered clinically
relevant.
HCV protease inhibitors
Simeprevir 200 mg daily Simeprevir: It is not recommended to
(ritonavir 100 mg BID) AUC: ↑ 7.2-fold co-administer Kaletra and
Cmax: ↑ 4.7-fold simeprevir.
Cmin: ↑ 14.4-fold
Herbal products
St John’s wort (Hypericum Lopinavir: Herbal preparations containing St
perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels.
Lopinavir and ritonavir levels may
increase on stopping
St John’s wort. The dose of
Kaletra may need adjusting. The
inducing effect may persist for at
least 2 weeks after cessation of
treatment with St John’s wort (see
section 4.3). Therefore, Kaletra
can be started safely 2 weeks after
cessation of St John's wort.
Immunosuppressants
Cyclosporin, Sirolimus Cyclosporin, Sirolimus More frequent therapeutic
(rapamycin), and (rapamycin), Tacrolimus: concentration monitoring is
Tacrolimus Concentrations may be increased recommended until plasma levels
due to CYP3A inhibition by of these products have been
lopinavir/ritonavir. stabilised.
Lipid lowering agents
Lovastatin and Simvastatin Lovastatin, Simvastatin: Since increased concentrations of
Markedly increased plasma HMG-CoA reductase inhibitors
concentrations due to CYP3A may cause myopathy, including
inhibition by lopinavir/ritonavir. rhabdomyolysis, the combination
of these agents with Kaletra is
contraindicated (see section 4.3).
Lipid-modifying agents
Lomitapide CYP3A4 inhibitors increase the Concomitant use of Kaletra with
exposure of lomitapide, with lomitapide is contraindicated (see
strong inhibitors increasing prescribing information for
exposure approximately 27-fold. lomitapide) (see section 4.3).
Due to CYP3A inhibition by
lopinavir/ritonavir, concentrations
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) protease (HOS-085623) lovastatin (HOS-086157) pibrentasvir (HOS-086298) lomitapide (HOS-086160) simvastatin (HOS-086158) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) tacrolimus (HOS-085202) velpatasvir (HOS-108929) simeprevir (HOS-086302) sirolimus (HOS-085172)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage d661859df9e7416124e84f058321f8363c31c96c6c3cbfadb04946272feb4ff7 · Zeichen 52766–57555 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 59
HOS-109021 · Präparat HOS-093083
Lopinavir: ↔
Glecaprevir/pibrentasvir Serum concentrations may be Concomitant administration of
increased due to P-glycoprotein, glecaprevir/pibrentasvir and Kaletra
BCRP and OATP1B inhibition by is not recommended due to an
lopinavir/ritonavir. increased risk of ALT elevations
associated with increased glecaprevir
exposure.
Sofosbuvir/velpatasvir/ Serum concentrations of It is not recommended to
voxilaprevir sofosbuvir, velpatasvir and coadminister Kaletra and
voxilaprevir may be increased due sofosbuvir/velpatasvir/ voxilaprevir.
to P-glycoprotein, BCRP and
OATP1B1/3 inhibition by
lopinavir/ritonavir. However, only
the increase in voxilaprevir
exposure is considered clinically
relevant.
HCV protease inhibitors
Simeprevir 200 mg Simeprevir: It is not recommended to
daily (ritonavir 100 mg AUC: ↑ 7.2-fold co-administer Kaletra and simeprevir.
BID) Cmax: ↑ 4.7-fold
Cmin: ↑ 14.4-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) protease (HOS-085623) pibrentasvir (HOS-086298) glecaprevir (HOS-086297) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage a7ffd699710dfcc905a1f28162df38c655a626dd6695d2536a15fef3b5c330fb · Zeichen 50777–52256 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94–95
HOS-109100 · Präparat HOS-093083
94
Sofosbuvir/velpatasvir/ Serum concentrations of It is not recommended to
voxilaprevir sofosbuvir, velpatasvir and coadminister Kaletra and
voxilaprevir may be increased due sofosbuvir/velpatasvir/
to P-glycoprotein, BCRP and voxilaprevir.
OATP1B1/3 inhibition by
lopinavir/ritonavir. However, only
the increase in voxilaprevir
exposure is considered clinically
relevant.
HCV protease inhibitors
Simeprevir 200 mg Simeprevir: It is not recommended to
daily (ritonavir 100 mg AUC: ↑ 7.2-fold co-administer Kaletra and
BID) Cmax: ↑ 4.7-fold simeprevir.
Cmin: ↑ 14.4-fold
Herbal products
St John’s wort Lopinavir: Herbal preparations containing St
(Hypericum perforatum) Concentrations may be reduced John’s wort must not be combined
due to induction of CYP3A by the with lopinavir and ritonavir. If a
herbal preparation St John’s wort. patient is already taking St John’s
wort, stop St John’s wort and if
possible check viral levels.
Lopinavir and ritonavir levels may
increase on stopping St John’s wort.
The dose of Kaletra may need
adjusting. The inducing effect may
persist for at least 2 weeks after
cessation of treatment with St
John’s wort (see section 4.3).
Therefore, Kaletra can be started
safely 2 weeks after cessation of St
John's wort.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) protease (HOS-085623) voxilaprevir (HOS-108930) velpatasvir (HOS-108929) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage ee23650cbabf756b8993f6c87d5c69ed1f0fde54c3889133693585c6c3314a93 · Zeichen 52603–55069 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-213942 · Präparat HOS-155234
6
HIV Integrase Strand Transfer Inhibitors
Raltegravir* raltegravir AUC ↑ 9% No dose adjustment is required.
raltegravir Cmin ↑ 27%
raltegravir Cmax ↑ 10%
rilpivirine AUC ↔
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Other Antiviral Agents
Ribavirin Not studied. No clinically relevant No dose adjustment is required.
drug-drug interaction is expected.
Simeprevir* simeprevir AUC ↔ No dose adjustment is required.
simeprevir Cmin ↔
simeprevir Cmax ↑ 10%
rilpivirine AUC ↔
rilpivirine Cmin ↑ 25%
rilpivirine Cmax ↔
OTHER AGENTS
ANTICONVULSANTS
Carbamazepine Not studied. Significant decreases Rilpivirine must not be used in
Oxcarbazepine in rilpivirine plasma concentrations combination with these
Phenobarbital are expected. anticonvulsants as co-administration
Phenytoin may result in loss of therapeutic effect
(induction of CYP3A enzymes) of rilpivirine (see section 4.3).
AZOLE ANTIFUNGAL AGENTS
Ketoconazole*# ketoconazole AUC ↓ 24% At the recommended dose of 25 mg
400 mg once daily ketoconazole Cmin ↓ 66% once daily, no dose adjustment is
ketoconazole Cmax ↔ required when rilpivirine is
co-administered with ketoconazole.
(induction of CYP3A due to high
rilpivirine dose in the study)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) ribavirin (HOS-088127) simeprevir (HOS-086302) raltegravir (HOS-086187) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage d0c8e2214f324cc8cea5f02abe5ea27e6465c6073be3cf8c9076f900047d4c89 · Zeichen 5501–7635 im Abschnitt
Wechselwirkungen · Edurant
EDURANT 2.5 mg dispersible tablets · Abschnitt 4.5 · PDF-Seite 29–30
HOS-214001 · Präparat HOS-155234
29
HIV Integrase Strand Transfer Inhibitors
Raltegravir* raltegravir AUC ↑ 9% No dose adjustment is required.
raltegravir Cmin ↑ 27%
raltegravir Cmax ↑ 10%
rilpivirine AUC ↔
rilpivirine Cmin ↔
rilpivirine Cmax ↔
Other Antiviral Agents
Ribavirin Not studied. No clinically relevant No dose adjustment is required.
drug-drug interaction is expected.
Simeprevir* simeprevir AUC ↔ No dose adjustment is required.
simeprevir Cmin ↔
simeprevir Cmax ↑ 10%
rilpivirine AUC ↔
rilpivirine Cmin ↑ 25%
rilpivirine Cmax ↔
OTHER AGENTS
ANTICONVULSANTS
Carbamazepine Not studied. Significant decreases Rilpivirine must not be used in
Oxcarbazepine in rilpivirine plasma concentrations combination with these
Phenobarbital are expected. anticonvulsants as co-administration
Phenytoin may result in loss of therapeutic effect
(induction of CYP3A enzymes) of rilpivirine (see section 4.3).
AZOLE ANTIFUNGAL AGENTS
Ketoconazole*# ketoconazole AUC ↓ 24% At the recommended doses once daily,
400 mg once daily ketoconazole Cmin ↓ 66% no dose adjustment is required when
ketoconazole Cmax ↔ rilpivirine is co-administered with
ketoconazole.
(induction of CYP3A due to high
rilpivirine dose in the study)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) ketoconazole (HOS-084513) carbamazepine (HOS-085618) ribavirin (HOS-088127) simeprevir (HOS-086302) raltegravir (HOS-086187) oxcarbazepine (HOS-110224) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-11T14:54:00Z · SHA-256 c02ae8018d7111133de16dc7b25339ee095e696ed781b3973764a15d8d998fed · Passage 575e291147f360507a5fb50ae7bdb3d61e7c10b0773ac174934ff5cd373e9c37 · Zeichen 5551–7618 im Abschnitt
Wechselwirkungen · Efavirenz Teva
Efavirenz Teva 600 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10–11
HOS-215280 · Präparat HOS-155418
10
Medicinal product by Effects on drug levels Recommendation concerning
therapeutic areas Mean percent change in AUC, co-administration with
(dose) Cmax, Cmin with confidence efavirenz
intervals if availablea
(mechanism)
Cmin: ↓ 44% reduction of boceprevir trough
Efavirenz: concentrations has not been
AUC: ↔ 20% directly assessed.
Cmax: ↔ 11%
(CYP3A induction - effect on
boceprevir)
*0-8 hours
No effect (↔) equals a decrease in
mean ratio estimate of ≤20% or
increase in mean ratio estimate of
≤25%
Telaprevir/efavirenz Telaprevir (relative to If efavirenz and telaprevir are co-
(1,125 mg q8h/600 mg once 750 mg q8h): administered, telaprevir 1,125 mg
daily) AUC: ↓ 18% (↓ 8 to ↓ 27) every 8 hours should be used.
Cmax: ↓ 14% (↓ 3 to ↓ 24)
Cmin: ↓ 25% (↓ 14 to ↓ 34)%
Efavirenz:
AUC: ↓ 18% (↓ 10 to ↓ 26)
Cmax: ↓ 24% (↓ 15 to ↓ 32)
Cmin: ↓ 10% (↑ 1 to ↓ 19)%
(CYP3A induction by efavirenz)
Simeprevir/efavirenz Simeprevir: Concomitant administration of
(150 mg once daily /600 mg once AUC: ↓71% (↓67 to ↓74) simeprevir with efavirenz resulted
daily) Cmax: ↓51% (↓46 to ↓56) in significantly decreased plasma
concentrations of simeprevir due
Cmin: ↓91% (↓88 to ↓92)
to CYP3A induction by efavirenz,
Efavirenz: which may result in loss of
AUC: ↔ therapeutic effect of simeprevir.
Cmax: ↔ Co-administration of simeprevir
Cmin: ↔ with efavirenz is not
No effect (↔) equals a decrease in recommended.
mean ratio estimate of ≤20% or
increase in mean ratio estimate of
≤25%
(CYP3A4 enzyme induction)
Sofosbuvir/velpatasvir ↔sofosbuvir Concomitant administration of
↓velpatasvir sofosbuvir/velpatasvir with
efavirenz resulted in a
↔efavirenz
reduction (approximately
50%) in the systemic exposure
of velpatasvir. The mechanism
of the effect on velpatasvir is
induction of CYP3A and
CYP2B6 by efavirenz.
Coadministration of
sofosbuvir/velpatasvir with
efavirenz is not recommended.
Refer to the prescribing
information for
sofosbuvir/velpatasvir for
more information.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) telaprevir (HOS-090618) boceprevir (HOS-090617) velpatasvir (HOS-108929) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-03-03T18:18:00Z · SHA-256 d2c4a637bb18ba1e0c98c69218ce14671957659a5aa55fba40e74b1bf5620382 · Passage baf3de0ce331552ab4e8a0d66b808da705c2aa678bebe78ae93bc0e3a2c80fc0 · Zeichen 18844–23796 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-138673 · Präparat HOS-098240
Daclatasvir/ Rilpivirine
Rilpivirine
Simeprevir/ Dolutegravir No dose adjustment is required.
Dolutegravir
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): daclatasvir (HOS-119742) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 65c050f1827ae903e3c393a7edc6d5b3e293d7637190b5a252bc6aa36f0d031c · Zeichen 6348–6489 im Abschnitt
Wechselwirkungen · Juluca
Juluca 50 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-138675 · Präparat HOS-098240
Simeprevir/ Rilpivirine
Rilpivirine AUC
Cmin 25%
Cmax
Simeprevir
AUC
Cmin
Cmax 10%
Sofosbuvir / Dolutegravir No dose adjustment is required.
Dolutegravir1 (Not studied)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sofosbuvir (HOS-108928) simeprevir (HOS-086302)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-14T16:39:00Z · SHA-256 0933317665b752128ea731fe5d180ec3ebff8bd69929c361b4010ae11184c9c5 · Passage 8d5a901f878eadcf3c59b9263bda75b4feb4697888ef4559eb608652752d4643 · Zeichen 6491–6894 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg film-coated tablets PREVYMIS 480 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-139778 · Präparat HOS-098408
Inhibitors of OATP1B1 or 3
Co-administration of letermovir with medicinal products that are inhibitors of OATP1B1/3
transporters may result in increased letermovir plasma concentrations. If letermovir is co-administered
with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of letermovir is 240 mg
once daily in adult and paediatric patients weighing at least 30 kg (see Table 1 and sections 4.2 and
5.2). If oral letermovir is co-administered with cyclosporine in paediatric patients weighing less than
30 kg, the dose should be decreased (see sections 4.2 and 5.2). Caution is advised if other OATP1B1/3
inhibitors are added to letermovir combined with cyclosporine.
-Examples of OATP1B1 inhibitors include gemfibrozil, erythromycin, clarithromycin, and several
protease inhibitors (atazanavir, simeprevir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) gemfibrozil (HOS-088403) clarithromycin (HOS-084517) erythromycin (HOS-084514) simeprevir (HOS-086302) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 7b2750dd16720be0c5053ed5563271404b3d4df02dd32109cb82953c2d70fdeb · Zeichen 2090–2916 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 240 mg concentrate for solution for infusion PREVYMIS 480 mg concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 39
HOS-139854 · Präparat HOS-098408
Inhibitors of OATP1B1 or 3
Co-administration of letermovir with medicinal products that are inhibitors of OATP1B1/3
transporters may result in increased letermovir plasma concentrations. If letermovir is co-administered
with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of letermovir is 240 mg
once daily in adult and paediatric patients weighing at least 30 kg (see Table 2 and sections 4.2 and
5.2). If intravenous letermovir is co-administered with cyclosporine in paediatric patients weighing
less than 30 kg, dose adjustment is not required (see Table 2 and sections 4.2 and 5.2). Caution is
advised if other OATP1B1/3 inhibitors are added to letermovir combined with cyclosporine.
-Examples of OATP1B1 inhibitors include gemfibrozil, erythromycin, clarithromycin, and several
protease inhibitors (atazanavir, simeprevir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) gemfibrozil (HOS-088403) clarithromycin (HOS-084517) erythromycin (HOS-084514) simeprevir (HOS-086302) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage 248c70c07d2b4f72a26bb2904cffb47a0df6f8f50d5d13e99be906410ca6b10b · Zeichen 2091–2939 im Abschnitt
Wechselwirkungen · Prevymis
PREVYMIS 20 mg granules in sachet PREVYMIS 120 mg granules in sachet · Abschnitt 4.5 · PDF-Seite 73
HOS-139921 · Präparat HOS-098408
Inhibitors of OATP1B1 or 3
Co-administration of letermovir with medicinal products that are inhibitors of OATP1B1/3
transporters may result in increased letermovir plasma concentrations. If letermovir is co-administered
with cyclosporine (a potent OATP1B1/3 inhibitor), the recommended dose of letermovir is 240 mg
once daily in adult and paediatric patients weighing at least 30 kg (see Table 2 and sections 4.2 and
5.2). If oral letermovir is co-administered with cyclosporine in paediatric patients weighing less than
30 kg, the dose should be decreased (see sections 4.2 and 5.2). Caution is advised if other OATP1B1/3
inhibitors are added to letermovir combined with cyclosporine.
-Examples of OATP1B1 inhibitors include gemfibrozil, erythromycin, clarithromycin, and several
protease inhibitors (atazanavir, simeprevir).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atazanavir (HOS-086180) protease (HOS-085623) gemfibrozil (HOS-088403) clarithromycin (HOS-084517) erythromycin (HOS-084514) simeprevir (HOS-086302) cyclosporine (HOS-084512)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-12T02:00:00Z · SHA-256 db4998a6cb590006789107af9f09c4196d815ed441a57d076042c2223b8d34a9 · Passage c2c8abacf4dc429d0ae21fadf956d0d42561c1bbc292251aaed3f1c108ba18c6 · Zeichen 2091–2917 im Abschnitt
Wechselwirkungen · Hepcludex
HEPCLUDEX 2 mg powder for solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-142397 · Präparat HOS-098824
In vitro an inhibition of OATP1B1/3 transporters by bulevirtide was observed, albeit only at a
concentration ≥ 0.5 µM, which is only reached in vivo after administration of high bulevirtide doses
(10 mg subcutaneous). The clinical relevance of these findings is unknown. As a precautionary
measure, close clinical monitoring is warranted when OATP1B1/3 substrates (e.g. atorvastatin,
bosentan, docetaxel, fexofenadine, glecaprevir, glyburide (glibenclamide), grazoprevir, nateglinide,
paclitaxel, paritaprevir, pitavastatin, pravastatin, repaglinide, rosuvastatin, simeprevir, simvastatin,
olmesartan, telmisartan, valsartan, voxilaprevir) are co-administered. When possible, co-
administration of these substrates should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fexofenadine (HOS-086255) atorvastatin (HOS-086304) simvastatin (HOS-086158) rosuvastatin (HOS-086307) glecaprevir (HOS-086297) olmesartan (HOS-112363) docetaxel (HOS-084505) glyburide (HOS-109273) voxilaprevir (HOS-108930) grazoprevir (HOS-108815) simeprevir (HOS-086302) telmisartan (HOS-085187) paclitaxel (HOS-087959) valsartan (HOS-088810) nateglinide (HOS-089675) bosentan (HOS-086291) paritaprevir (HOS-110301) repaglinide (HOS-086935) pravastatin (HOS-086306) pitavastatin (HOS-125743)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-03-31T10:15:00Z · SHA-256 56ea5f48399773f9051c5a5cc519d740db7ee3cdff519ad40c96b180c39a4a0f · Passage e4ef1700e52190dc95fda7461e5b1ebeb8be97d2217f6773b4c102817dc6b0b5 · Zeichen 663–1396 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.